CFDE Data Portal | Search MIR193BHG

	Label	Description
	MIR193BHG Gene (Entity type)	ENSG00000262454 - MIR193b-365a host gene
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 nifurtimox A-549 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS

MIR193BHG

ENSG00000262454 - MIR193b-365a host gene

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

A Gene Set from LINCS

GSE193541 nifurtimox A-549 1 v 2 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE108464 AZ-628 6 v 15 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.